Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company, is approaching a key milestone, representing a critical step toward regulatory submission, potential approval, and the company's first commercial launch.
The company's lead drug candidate is Azetukalner, which is being explored in the indications of epilepsy, major depressive disorder, and bipolar depression.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com